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A functional single nucleotide polymorphism (SNP) in the 
catechol-O-methyltransferase (COMT) gene mapped to chro-
mosome 22q11 is thought to inﬂ  uence dopamine concentra-
tion in the prefrontal cortex (Akil et al., 2003; Chen et al., 2004; 
Lachman et al., 1996). COMT is a post-synaptic enzyme that 
catabolizes dopamine released in the prefrontal cortex, and a 
valine (Val) to methionine (Met) amino acid substitution at the 
158/108 locus of the peptide sequence affects the thermostabil-
ity of the enzyme. The Met/Met form of this polymorphism 
produces a less active enzyme resulting in higher dopamine 
levels than the Val/Val or the Val/Met polymorphism. In schiz-
ophrenic populations, as well as normal functioning young 
adults, the Met/Met form of the COMT polymorphism has been 
related to superior performance on a number of tests of execu-
tive function including the Wisconsin Card Sort Task (Egan 
et al., 2001; Joober et al., 2002; Malhotra et al., 2002) and the 
n-back task (Goldberg et al., 2003). In addition, people with the 
Met/Met form of the COMT polymorphism can elicit higher 
or lower levels of activity in the prefrontal cortex depending 
on the task characteristics and cognitive demands (Bertolino 
et al., 2006; Caldu et al., 2007; Egan et al., 2001; Ettinger et al., 
2008; Mattay et al., 2003; Winterer et al., 2006). However, some 
studies, including a recent meta-analysis have reported that 
Genetic contributions to age-related decline in executive 
function: a 10-year longitudinal study of COMT and 
BDNF polymorphisms
Kirk I. Erickson1,2,3,*, Jennifer S. Kim2,3, Barbara L. Suever4, Michelle W. Voss1,3, 
B. Magnus Francis5 and Arthur F. Kramer1,2,3
1. Psychology Department, University of Illinois at Urbana-Champaign, Champaign, IL, USA
2. Neuroscience Program, University of Illinois at Urbana-Champaign, Urbana, IL, USA
3. Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA
4. School of Integrative Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA
5. Entomology Department, University of Illinois at Urbana-Champaign, Urbana, IL, USA
Edited by:  William J. Jagust, University of California Berkeley, USA
Reviewed by:  Cheryl Grady, University of Toronto, Canada
  Roshan Cools, University of Cambridge, UK
Genetic variability in the dopaminergic and neurotrophic systems could contribute to age-related impairments in executive control 
and memory function. In this study we examined whether genetic polymorphisms for catechol-O-methyltransferase (COMT) and brain-
derived neurotrophic factor (BDNF) were related to the trajectory of cognitive decline occurring over a 10-year period in older adults. 
A single nucleotide polymorphism in the COMT (Val158/108Met) gene affects the concentration of dopamine in the prefrontal cortex. In 
addition, a Val/Met substitution in the pro-domain for BDNF (Val66Met) affects the regulated secretion and trafﬁ  cking of BDNF with Met 
carriers showing reduced secretion and poorer cognitive function. We found that impairments over the 10-year span on a task-switching 
paradigm did not vary as a function of the COMT polymorphism. However, for the BDNF polymorphism the Met carriers performed worse 
than Val homozygotes at the ﬁ  rst testing session but only the Val homozygotes demonstrated a signiﬁ  cant reduction in performance over 
the 10-year span. Our results argue that the COMT polymorphism does not affect the trajectory of age-related executive control decline, 
whereas the Val/Val polymorphism for BDNF may promote faster rates of cognitive decay in old age. These results are discussed in 
relation to the role of BDNF in senescence and the transforming impact of the Met allele on cognitive function in old age.
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INTRODUCTION
Old age is often accompanied by cognitive impairment with 
the largest deﬁ  cits on executive control tasks that are reliant 
on prefrontal cortex function (Hedden and Gabrieli, 2004). 
Evidence from both humans and non-human animals sug-
gests that some cognitive deﬁ  cits observed in old age could be 
related to disruptions in the dopaminergic and neurotrophic 
systems (Bäckman et al., 2006; Pang and Lu, 2004). For this 
reason, genetic polymorphisms that affect the concentration 
or secretion of neurotrophic factors and neurotransmitters 
could contribute to some of the individual differences in cog-
nitive function in older adults (de Frias et al., 2004; Harris 
et al., 2006).
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the Met/Met form of the COMT polymorphism is not always 
associated with enhanced or more efﬁ  cient cognitive function 
or prefrontal activity compared to Val carriers (Barnett et al., 
2008; Bruder et  al., 2005; Ho et  al., 2005; MacDonald et  al., 
2007; Tsai et al., 2003).
A few studies have examined whether individual differences 
in cognitive function in non-demented older adults could be 
attributed to the COMT polymorphism. One study found no 
association between the COMT polymorphism and cognitive 
function (O’Hara et al., 2006) while others have reported better 
cognitive performance in Met homozygotes compared to carri-
ers of the Val allele (de Frias et al., 2004; Liu et al., 2008). On the 
other hand, some studies have reported better cognitive func-
tion in the Val/Met heterozygotes than either of the homozy-
gotes (Harris et al., 2005), and yet others have reported that 
both Val/Met heterozygotes and Met homozygotes perform bet-
ter than the Val/Val counterparts (Starr et al., 2007). Some have 
speculated that this variation in the literature could be related 
to (a) an age-related shift in the U-shaped curve that reﬂ  ects 
dopamine signaling in the prefrontal cortex (Harris et al., 2005; 
Starr et al., 2007), (b) that COMT interactions with gender and 
age (O’Hara et al., 2006) could be masking or driving certain 
effects, or (c) the tasks that are employed in some studies do 
not adequately and speciﬁ  cally reﬂ  ect dopamine or prefron-
tal cortex engagement and therefore do not validly reﬂ  ect the 
impact that the polymorphism has on prefrontal function 
(O’Hara et al., 2006). There are also a number of other expla-
nations for the discrepancies found between studies including 
interactions or covariation between the COMT polymorphism 
and lifestyle factors, demographic variables, or other genes or 
polymorphisms.
Most of the studies described above have utilized cross-
  sectional designs, that is, they assess the relationship between 
the COMT polymorphism and cognitive function at one point 
in time. This method is capable of assessing whether any asso-
ciation exists between the COMT polymorphism and cognition 
but cannot determine if the polymorphism accounts for within-
subject change in cognitive function across the lifespan. In order 
to assess whether the polymorphism relates to the trajectory 
of cognitive decline in old age, longitudinal investigations are 
needed. Two longitudinal studies have examined the effects of 
the COMT polymorphism on the trajectory of cognitive decline 
in older adults. The ﬁ  rst study reported that Met homozygotes 
between 50 and 60 years old experienced a more rapid decline in 
episodic memory performance over a 5-year period than Val car-
riers of the same age (de Frias et al., 2004). However, the COMT 
polymorphism did not moderate changes in episodic memory in 
either middle-aged adults or adults between 65 and 80 years of 
age. The main conclusion was that change in episodic memory 
over a 5-year period is largely independent of the COMT poly-
morphism except in younger-old adults, that is people between 
50 and 60 years of age. A second longitudinal study, with a 
  follow-up period of 4 years, reported that there was no interac-
tion between the COMT polymorphism and time on cognitive 
function in people between 60 and 64 years of age. However, 
there was a signiﬁ  cant effect of the COMT polymorphism after 
controlling for general cognitive function at age 11, suggesting 
that there was a change in the effect that the polymorphism had 
on cognitive function over the lifespan (Starr et al., 2007). These 
results suggest that if the effect of the COMT polymorphism on 
cognitive performance changes as a function of age, the changes 
occur before the age of 60.
Although the dopaminergic system has been proposed to 
underlie some of the age-related cognitive deﬁ  cits in prefron-
tal function (Bäckman et al., 2006), it is likely that changes in 
the concentration or efﬁ  cacy for an array of molecules and 
receptors inﬂ  uences cognitive function in old age. For example, 
brain-derived neurotrophic factor (BDNF) is another molecule 
involved in cognition that may be related to cognitive impair-
ment and dementia. For example, the mature form of the BDNF 
(mBDNF) molecule enhances learning and memory and long-
term potentiation (Pang et al., 2004), induces synaptic plasticity 
(Lu, 2003), and promotes neurogenesis (Pencea et al., 2001) and 
there is evidence that age-related cognitive impairments might 
be related to a decrease in the production or secretion of BDNF 
(Hayashi et al., 2001; Pang and Lu, 2004).
A functional polymorphism in the gene for BDNF produces 
a single amino acid substitution of Val to Met at codon 66 in the 
pro-domain, with the Met allele selectively impairing the regu-
lated secretion and intracellular trafﬁ  cking of BDNF in primary 
cortical neurons and neurosecretory cells (Chen et al., 2004; Egan 
et al., 2003). Previous studies have found that  people with the Met 
allele have impaired episodic memory, working memory, and 
hippocampal function (Egan et al., 2003; Hariri et al., 2003; Ho 
et al., 2006) and lower hippocampal   levels of N-acetylaspartate, 
a putative measure of neuronal integrity (Egan et al., 2003). In 
addition, Met carriers have less gray matter volume throughout 
the prefrontal and middle temporal lobes compared to Val carri-
ers (Ho et al., 2006, 2007; Pezawas et al., 2004).
Only a few studies have examined the relationship between 
the BDNF polymorphism and age-related cognitive impairment. 
Inconsistent with the majority of studies in young adults and 
patients with depression, Met homozygotes at 64 and 79 years 
of age outperformed the Val homozygotes and heterozygotes 
(Harris et al., 2006) after controlling for sex and cognitive per-
formance at age 11. This ﬁ  nding suggests that the inﬂ  uence 
that BDNF has on cognitive function may change across the 
lifespan and that the Met allele may be neuroprotective during 
later stages of life. Consistent with this ﬁ  nding, there is some 
evidence that the Val allele may increase the risk for Alzheimer’s 
disease (Matsushita et al., 2005; Ventriglia et al., 2002), but some 
recent studies have failed to ﬁ  nd such a relationship (Akatsu 
et al., 2006; He et al., 2007). Others however have reported the 
opposite ﬁ  nding, that is older adults carrying the Met allele per-
form worse across a variety of cognitive domains compared with 
the Val homozygotes (Miyajima et al., 2008) and have a higher 
risk for developing late-life depression (Taylor et al., 2007) and 
white-matter hyperintensities (Taylor et  al., 2008). However, 
similar to the research on COMT, the studies mentioned above 
on BDNF have been cross-sectional in nature and are therefore 
limited in their capability for drawing conclusions concerning 
the relationship between within-subject changes in cognitive 
function and the BDNF polymorphism. A longitudinal study 
would help resolve these issues.
The current study assessed whether cognitive decline over a 
10-year span in a group of older adults was moderated by the 
COMT and/or BDNF polymorphism. Our within-subject design 
provided us with more statistical power than previously con-
ducted cross-sectional studies. To assess whether individual dif-
ferences in cognitive decline varied as a function of the BDNF or 
COMT polymorphism we utilized a well-studied task-switching 
paradigm that requires participants to rapidly switch between 
one simple cognitive task to a different cognitive task (Rogers 
and Monsell, 1995). This paradigm was chosen because of its www.frontiersin.org
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established capability to tap prefrontal and executive resources 
(Braver et al., 2003; Kimberg et al., 2000) and to demonstrate 
age-related deﬁ  cits (Kramer et al., 1999a; Kray and Lindenberger, 
2000). Therefore, this paradigm allowed us to test the prediction 
that (a) the COMT and BDNF polymorphisms affect perform-
ance on tasks that depend on prefrontal function, and (b) age-
related executive deﬁ  cits vary as a function of the BDNF or 
COMT polymorphism. Furthermore, our 10-year longitudinal 
design doubles the length of previous longitudinal studies to 
date. A long span between testing periods increases the likelihood 
of ﬁ  nding changes in cognitive function across time, which then 
provides us with the variation necessary to assess whether the 
COMT and/or BDNF polymorphisms moderates the decline in 
performance. Based on the extant literature, we predicted that 
the COMT polymorphism would explain little of the changes in 
cognitive performance over the 10-year span given that the age 
of our sample at the ﬁ  rst time point was on average above the 
age in which interactions across the lifespan have been observed 
in prior investigations (de Frias et al., 2004). On the other hand, 
there have not been any longitudinal studies examining whether 
the BDNF polymorphism inﬂ  uences cognitive function across 
the adult lifespan. Some have argued that at younger ages, the 
Val/Val allelic combination provides some neuronal and cogni-
tive beneﬁ  ts, but with advancing age the Met allele, instead of 
being detrimental to cognitive and brain function and morphol-
ogy, actually carries some protection against the development 
of dementia and cognitive impairment (Harris et al., 2006). We 
explored these hypotheses in the current study.
MATERIALS AND METHODS
PARTICIPANTS
Fifty-three healthy older adults (14 male, mean age of 75.5 ± 5.3, 
range: 67–86) who had participated in a previous study ∼10 years 
ago (Kramer et al., 1999b) were recruited to participate in this 
study. Forty-three percent of the original sample of 124 par-
ticipants agreed to return. We assessed whether the participants 
who agreed to return for the follow-up session were different 
from those who declined the invitation to return for the fol-
low-up session in terms of male to female ratio or age. The male 
to female ratio was similar between those that agreed to return 
(m:f = 0.35) versus those that declined the invitation to return 
(m:f = 0.38), with slightly more men declining the invitation to 
return for the follow-up. Furthermore, the average age of the par-
ticipants was nearly equivalent for those that returned [average 
age = 65.33 (10 years ago)] compared with those that declined 
to return for the follow-up session [average age = 65.50 (10 years 
ago)]. Independent samples t-tests demonstrated that these dif-
ferences were not signiﬁ  cant (all p >  0.05). The University of 
Illinois Institutional Review Board approved the study, and all 
volunteers signed an informed consent.
TASK-SWITCHING
The task-switching paradigm examines subjects’ ability to rap-
idly disengage from the performance of one task and switch to 
another. Subjects performed two different tasks that alternated 
after every two trials – two trials of one task followed by two 
  trials of the other task and so on (see Figure 1). In one task sub-
jects performed an odd/even numerical judgment (i.e., is a single 
digit number odd or even). In the other task subjects performed 
a vowel/consonant judgment. When one type of trial (e.g., digit 
judgment) was followed by a trial of the same type (e.g., digit 
judgment) it was labeled a Repeat trial. However, when parti-
cipants needed to respond to a trial that was of a different task 
type than the previous trial, it was labeled as a Switch. Response 
times (RTs) to switch trials are higher than RTs to repeat trials 
and the accuracy rates are lower.
Figure 1 | Description of the task-switching paradigm. Letter and digit stimuli were presented simultaneously in a 2 × 2 grid and participants had to switch 
between responding to the letters versus responding to the numbers on every 3rd trial (adapted from Rogers and Monsell, 1995).Frontiers in Human Neuroscience  | September  2008 | Volume  2 | Article  11
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The task stimuli, a letter and a single digit number, were 
presented together in a 2 × 2 matrix centered in the middle of 
the computer screen. When the letter and digit were located in 
one half of the matrix subjects performed the odd/even judg-
ment task, when the letter and digit were in the other half of 
the matrix subjects performed the consonant/vowel judgment 
task (e.g., perform odd/even judgment for upper two quadrants 
of the matrix and consonant/vowel judgment for lower two 
quadrants). The letter and digit were presented in the matrix 
in a continuous clockwise direction. Thus, the occurrence of a 
task switch was predictable. The location (i.e., left, right, upper, 
lower) of each task was counterbalanced across subjects (task 
adapted from Rogers and Monsell, 1995).
Each stimulus pair was presented until the subject responded 
and then the next stimulus pair was presented 400 ms following 
response. Subjects responded with one of two keys on the com-
puter keyboard for both of the tasks (e.g., one key was used to 
respond to an odd number or a consonant). The key representa-
tions were counterbalanced across subjects.
Subjects ﬁ  rst performed two 30 trial single task blocks fol-
lowed by one 30 trial task-switching block as practice. The prac-
tice blocks were then followed by four 60 trial task-switching 
blocks. The main dependent variables included mean RT and 
accuracy to both Repeat and Switch conditions.
MMSE AND IQ
To test for general cognitive function and possible dementia we 
employed a modiﬁ  ed and revised version of the Mini-Mental 
Status Examination (MMSE) that has a high score of 57 and a 
cut-off for possible dementia at 51. To assess the relationship 
between the BDNF and COMT polymorphisms and general 
intelligence (IQ) we employed the Kaufman Brief Intelligence 
Test. Both of these tests were conducted at the Time 2 session 
and were therefore not subjected to a repeated-measures analy-
sis to assess for change in either score.
GENOTYPING
Buccal cells were collected from all participants using 
MasterAmp™ Buccal Swab Brushes (Epicentre Biotechnologies). 
Genomic deoxyribonucleic acid (DNA) was extracted from the 
buccal swabs using MasterAmp™ DNA Extraction Solution 
(Epicentre Biotechnologies).
COMT
Primers COMT-F 5′-TCA CCA TCG AGA TCA ACC CC-3′ and 
COMT-R 5′-GAA CGT GGT GTG AAC ACC TG-3′ were used 
to amplify the 176 bp polymorphic COMT fragment (Barr et al., 
1999). The ampliﬁ  cation was done in 50 μl reactions containing 
∼125 ng genomic DNA, 200 μM deoxynucleoside triphosphates 
(dNTPs), 10  pmol/l of each primer, 10× HotStarTaq® buffer 
(QIAGEN), and 1 U HotStarTaq® DNA polymerase (QIAGEN). 
Polymerase chain reaction (PCR) conditions consisted of an ini-
tial denaturation step at 95°C for 15 min followed by 30 cycles 
on a thermocycler (denaturation at 94°C for 30 s, annealing 
at 52°C for 30 s, and extension at 72°C for 30 s) and ﬁ  nished 
with a ﬁ  nal extension at 72°C for 10 min. Eight microliters of 
the PCR product were digested with 10 U NlaIII (New England 
Biolabs) (Barr et al., 1999) at 37°C for 1 h and analyzed by gel 
electrophoresis on a 3.5% MetaPhor® agarose gel (Cambrex 
Bioscience, Inc./Lonza). The gel was immersed in an ethidium 
bromide solution for 15 min and visualized under ultraviolet 
light. Digestion resulted in bands of 82, 54, and 41 bp for the 
Val158 allele. The 82 bp fragment was cut into 64 and 18 bp bands 
for the Met158 allele.
BDNF
Primers BDNF-F 5′-GAG GCT TGA CAT CAT TGG CT-3′ and 
BDNF-R 5′-CGT GTA CAA GTC TGC GTC CT-3′ were used to 
amplify the 113 bp polymorphic BDNF fragment (Neves-Pereira 
et al., 2002). The ampliﬁ  cation was done in 25 μl reactions con-
taining ∼125 ng genomic DNA, 200 μM dNTPs, 10 pmol of each 
primer, 1.5 mM MgCl2, 1 U Taq DNA polymerase (Invitrogen) 
(adapted from Neves-Pereira et al., 2002). PCR conditions con-
sisted of an initial denaturation step at 95°C for 5 min followed 
by 30 cycles on a thermocycler (denaturation at 94°C for 30 s, 
annealing at 60°C for 30 s, and extension at 72°C for 30 s) and 
ﬁ  nished with a ﬁ  nal extension at 72°C for 5 min (Neves-Pereira 
et al., 2002). 6.5 μl of the PCR product were digested with 3 U 
Eco721 (Fermentas) at 37°C overnight and analyzed by gel electro-
phoresis on a 4% 3:1 NuSieve® agarose gel (Cambrex Biosciences, 
Inc./Lonza) (adapted from Neves-Pereira et al., 2002). The gel 
was immersed in an ethidium bromide solution for 10 min and 
visualized under ultraviolet light. Digestion resulted in an uncut 
band of 113 bp for the Met66 allele. The 113 bp fragment is cut 
into 78 and 35 bp bands for the Val66 allele.
STATISTICAL ANALYSIS
We analyzed the task-switching data (reaction time and accuracy) 
with repeated-measures analyses of variance with Time (1997, 
2007) and Condition (repeat, switch) as within-subject factors 
and group (COMT or BDNF genotype) as a between-subjects 
factor. Effect sizes were calculated and reported here as partial eta-
squared (η2
p). IQ scores were used as a covariate for COMT (see 
‘Results’ section). One-way ANOVAs and independent samples 
t-tests were also employed to assess differences in demographic 
characteristics, IQ, MMSE scores, or task-  switching performance 
as a function of the BDNF and COMT polymorphism at separate 
time points. All data was analyzed using SPSS 16.02 for Mac.
RESULTS
COMT
Demographics
One-way ANOVAs were used to test whether the COMT SNP 
was related to age or IQ (see Table 1). We found no effect of age 
[F(2,52) = 1.87; n.s; η2
p = 0.07], but we did ﬁ  nd a trend for an 
effect of IQ obtained from the Kaufman Brief Intelligence Scale 
[F(2,52) = 2.61; p < 0.08; η2
p = 0.09]. Post hoc tests revealed that 
those with the Val/Val form of the COMT gene had lower IQ 
scores than the heterozygotes (p < 0.04) and marginally lower 
scores than the Met homozygotes (p <  0.06). Met homozy-
gotes and Val/Met heterozygotes did not differ in IQ scores 
(p < 0.92).
MMSE
We employed a one-way ANOVA to examine whether the 
COMT SNP was related to performance on the MMSE task – a 
general and widely used measure to test for possible dementia 
and impaired cognitive function (see Table 1). There was no 
relationship between the COMT SNP and performance on the 
MMSE [F(2,51) = 1.84; n.s.; η2
p = 0.07].
Task-switching
Repeated-measures ANOVAs were run with COMT genotype 
(Val/Val; Val/Met; Met/Met) as a between-subjects factor and www.frontiersin.org
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Time (1997 – Time 1; 2007 – Time 2) and Condition (Repeat; 
Switch) as within-subjects factors on RTs and accuracy rates 
separately. We included IQ score as a covariate given its mar-
ginal relationship to the COMT polymorphism (see above). 
Therefore, all results described here can be considered to be 
  statistically independent from IQ.
We found that main effects of Time [F(1,42) = 1.75; n.s.] and 
Genotype [F(2,42) = 1.23; n.s.] were not signiﬁ  cant (Table 2). 
Furthermore, consistent with our hypotheses and results from 
previous studies (de Frias et al., 2004; Harris et al., 2005) we 
failed to ﬁ  nd a Time × Genotype interaction [F(2,42) = 0.34; 
n.s.; η2
p = 0.02] or a Time × Genotype × Condition interaction 
on the RTs from the task-switching paradigm [F(2,42) = 0.30; 
n.s.; η2
p = 0.01]   indicating that RTs (for both the repeat and 
switch conditions) did not change over the 10-year period as 
a function of the COMT polymorphism. Converting the RTs 
into a switch cost (switch RT – repeat RT) at each time point 
conﬁ  rmed this effect. We also conducted the same repeated-
measures analysis on the accuracy rates and found neither a 
signiﬁ  cant Time × Genotype  interaction  [F(2,42) = 0.86;  n.s.; 
η2
p = 0.04]  nor  a  Time  × Genotype × Condition interaction 
[F(2,42) = 0.70; n.s.; η2
p = 0.03].
To assess performance on the task-switching paradigm at 
individual time points as a function of the COMT polymorphism 
we conducted a series of univariate ANOVAs with Genotype as a 
ﬁ  xed factor and RTs and accuracy rates for each condition as the 
dependent variable. There was no effect of Genotype on the RTs for 
either the switch condition or the repeat condition at either time 
point (all p > 0.05; all η2
p < 0.07). However, for the accuracy meas-
ures, we found that at Time 1 there was a   marginally   signiﬁ  cant 
effect of Genotype for the switch   condition [F(2,51) = 2.85; 
p < 0.06; η2
p = 0.11]. Post hoc comparisons revealed that the Met 
homozygotes had signiﬁ  cantly higher accuracy rates compared 
with the heterozygotes (p < 0.02), but were not reliably differ-
ent from the Val homozygotes (p < 0.63). No other comparisons 
reached signiﬁ  cance (all p > 0.05).
There were six participants who could not complete the 
task-switching paradigm at Time 2 because the task was too 
challenging, however these participants had been able to suc-
cessfully complete the task 10 years prior. Interestingly, ﬁ  ve out 
of the six participants had the Val/Val form of the COMT poly-
morphism and the other participant was heterozygous. None 
of the participants who failed to complete the task at Time 2 
were homozygous for the Met/Met form. We tested whether 
this distribution was signiﬁ  cantly different from chance using 
a χ2 non-parametric test with the respective sample sizes for 
each polymorphism as the null hypothesis (Val/Val = 16, Val/
Met = 19, Met/Met = 18). We found a non-signiﬁ  cant χ2 (1.05; 
p <  0.59) for the given   frequencies, indicating that although 
there were more Val homozygotes who failed to complete the 
task, the number of participants who fell into this category was 
not signiﬁ  cantly greater than chance. However, studies with 
larger samples could more validly test this trend.
BDNF
Demographics
We conducted independent samples t-tests to assess whether 
any demographics variables were related to the BDNF polymor-
phism (see Table 1). Neither age [t(1,51) = 0.78; n.s.] nor IQ 
[t(1,51) = 1.48; n.s.] was related to the BDNF polymorphism.
Table 1 | Demographic information, IQ, and MMSE scores are stratiﬁ  ed by both the COMT and BDNF polymorphism.
  N  Sex  Age (Time 1)  IQ  MMSE
COMT
  Val/Val  16  11F/5M  65.06 (5.60)  109.25 (14.09)  52.12 (5.29)
  Val/Met  19  16F/3M  68.16 (5.22)  116.16 (8.25)  53.42 (2.61)
  Met/Met  18  12F/6M  65.56 (4.68)  115.83 (6.28)  54.59 (2.78)
BDNF
  Val/Val  29  23F/6M  65.83 (5.47)  112.10 (10.45)  52.75 (4.44)
  Val/Met  24  16F/8M  66.96 (5.02)  116.21 (9.56)  54.17 (2.61)
 Met/Met    0  –  –  –  –
Standard deviations are represented in parentheses. There was a trend for IQ to vary as a function of COMT genotype and the Val/Val form of the polymorphism reliably differed from 
the Val/Met form.
Table 2 | Mean response times and accuracy rates for repeat and switch conditions for both BDNF and COMT polymorphisms.
  Time 1  Time 2
 Repeat  Switch  Repeat  Switch
  RT  ACC RT  ACC RT  ACC  RT  ACC
COMT
  Val/Val  1607.81 (585.45)  93.4 (6.9)  2402.61 (735.38)  95.6 (7.2)  1761.99 (831.38)  87.5 (18.5)  2511.97 (1330.52)  82.0 (18.9)
  Val/Met  1384.06 (488.63)  96.3 (6.9)  2120.85 (733.84)  94.3 (5.3)  1474.34 (344.05)  93.8 (10.1)  2311.68 (556.09)  89.2 (13.2)
  Met/Met  1271.42 (342.84)  99.5 (.66)  1912.09 (671.48)  98.0 (1.5)  1623.44 (583.15)  93.7 (11.5)  2221.41 (917.41)  90.6 (12.4)
BDNF
  Val/Val  1262.56 (287.31)  97.7 (4.9)  1902.27 (552.69)  95.9 (5.5)  1680.62 (640.42)  95.1 (4.7)  2471.60 (981.44)  89.2 (9.8)
  Val/Met  1536.32 (588.06)  97.4 (6.2)  2329.38 (822.82)  96.1 (4.5)  1515.12 (507.37)  89.1 (17.8)  2163.52 (825.08)  86.7 (18.5)
Standard deviations are represented in parentheses.Frontiers in Human Neuroscience  | September  2008 | Volume  2 | Article  11
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MMSE
In an independent samples t-test we found that there was no 
relationship between the BDNF polymorphism and perform-
ance on the MMSE [t(1,51) = 1.42; n.s. – see Table 1].
Task-switching
Similar to the COMT polymorphism described above, we 
assessed the inﬂ  uence of the BDNF polymorphism on   cognitive 
decline in the task-switching paradigm by employing a repeated-
 measures ANOVA with Genotype (Val/Val; Val/Met) as a between-
subjects factor and Time (1997 – Time 1; 2007 – Time 2) and 
Condition (Repeat; Switch) as within-subjects factors.
For BDNF, we found that main effects of Time [F(1,44) = 
2.13; n.s.] and Genotype [F(1,44)  =  0.09; n.s.] were not sig-
niﬁ  cant (Table 2). However, consistent with the view that the 
Met allele might   provide some protection in old age or that 
the Val   homozygotes might experience greater decline with 
advancing age, we found a signiﬁ  cant Time × Genotype inter-
action [F(1,44) = 7.54; p < 0.009; η2
p = 0.15] on RTs in the task-
  switching paradigm such that the Val homozygotes experienced 
a signiﬁ  cantly greater decline in performance over the 10-year 
period compared to the Met carriers (see Figure 2). There 
was also a trend for a Time × Genotype × Condition interac-
tion [F(1,44) = 3.15;  p < 0.08;  η2
p = 0.07]  such  that Val  carri-
ers experienced a greater decline in performance for the switch 
condition compared with the repeat condition over the 10-year 
span compared to the Met carriers. This trend was conﬁ  rmed by 
examining switch cost (switch RT – repeat RT). For the accu-
racy measures, neither the Time × Genotype interaction or the 
Time × Genotype ×  Condition interaction reached signiﬁ  cance 
Figure 2 | Results from the task-switching paradigm as a function of the BDNF polymorphism and Time for each condition. Only the Val/Val homozygotes 
experienced a decline in performance for both the repeat and switch conditions, whereas the Val/Met carriers showed no decline over the 10-year span.
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  indicating that unlike the RTs, the accuracy rates were not 
 inﬂ  uenced by the BDNF polymorphism. However, we found a 
signiﬁ  cant  Genotype × Condition  interaction  on  the accuracy 
rates [F(1,44) = 4.94; p < 0.03; η2
p = 0.10] with the Val homozy-
gotes performing better than the heterozygotes on the repeat 
condition compared to the switch condition.
We conducted a series of independent t-tests at each time 
point and for each condition separately to test whether the two 
groups differed at either time point. There were no signiﬁ  cant 
differences between the two BDNF polymorphisms at either 
time point for RTs or accuracy measures (all p > 0.05).
Like the COMT polymorphism results described above we 
examined whether the participants who could not complete 
the task-switching paradigm at Time 2 had a particular form of 
the BDNF polymorphism. The results from the χ2 test was not 
signiﬁ  cant (0.04; p < 0.83) indicating that the BDNF polymor-
phism did not explain the failure to complete the task-switching 
paradigm at Time 2.
DISCUSSION
In this study we examined whether the BDNF or COMT poly-
morphisms could explain variation in the trajectory of cogni-
tive decline over a 10-year span in older adults. Our participants 
were older than the participants in a previous 5-year longitudi-
nal study examining the inﬂ  uence of the COMT polymorphism 
on cognitive performance in older adults (de Frias et al., 2004). 
Furthermore, this is the ﬁ  rst known longitudinal study of the 
effects of the BDNF polymorphism on age-related cognitive 
decline.
Consistent with prior studies, we found no evidence that the 
COMT polymorphism contributes to age-related declines in 
executive function as assessed by the task-switching paradigm 
(O’Hara et al., 2006; Starr et al., 2007). In a longitudinal study, 
an interaction with age was only reported for people between 
50 and 60 years of age (de Frias et al., 2004). The participants 
in our sample were 65 years of age on average in 1997 and 
∼75 years of age as of 2007, and therefore may have been out-
side the age range to detect an interaction if such an interaction 
is speciﬁ  c to the 5th decade of life (de Frias et al., 2004). Our 
results are more consistent with a 4-year longitudinal study of 
older adults that did not ﬁ  nd an interaction between the COMT 
polymorphism and age on cognitive function (Starr et al., 2007). 
In short, our results suggest that, after the 6th decade of life, the 
COMT polymorphism does not explain cognitive decline over a 
10-year period.
On the other hand, the BDNF polymorphism reliably 
explained variation in age-related decline in performance for 
both the repeat and switch conditions of the task-switching 
paradigm (Figure 2). In a cross-sectional study, Harris et  al. 
(2006) reported that older adult Met homozygotes had better 
reasoning skills than Val homozygotes or heterozygotes. Partially 
consistent with this ﬁ  nding, we demonstrate that the Met carri-
ers have spared cognitive function over a 10-year period while 
the Val homozygotes showed a signiﬁ  cant decline in perform-
ance. These results, however, are generally inconsistent with the 
majority of the BDNF-gene literature, which typically reports 
poorer performance and functioning for Met carriers in both 
young and old adults (Egan et al., 2003; Taylor et al., 2007). This 
discrepancy between our ﬁ   nding and cross-sectional studies 
might be explained by the age of the sample studied. Based on 
our longitudinal results it is apparent that at an average age of 
65 the Val homozygotes tend to perform better than Met carri-
ers, however there is a crossover such that by the average age of 
75 Val homozygotes tend to perform worse than Met carriers. 
Cross-sectional studies that assess older adults around 65 years 
of age might ﬁ  nd cognitive enhancement associated with the 
Val/Val genotype, whereas studies examining a sample with an 
average age of 75 might produce the opposite pattern.
There are a number of possible reasons that could explain 
the crossover effect that we observed. First, we have no infor-
mation regarding the trajectory of cognitive decline earlier in 
life. Therefore, it is possible that Met carriers could have shown 
a decline in performance at an earlier age and then plateaued, 
while the Val homozygotes had spared cognitive function until 
the 6th to 7th decade of life.
Second, a number of factors that inﬂ  uence BDNF signaling 
could be altered during old age such that greater secretion of 
BDNF would be detrimental for cognitive and neural activity. 
For example, the precursor form of the BDNF (pro-BDNF) 
molecule and the mBDNF have distinct receptors and signal-
ing cascades resulting in opposing effects on the nervous system 
(Lu et al., 2005; Pang et al., 2004). Pro-BDNF enhances the capa-
bility for eliciting long-term depression, synaptic  retraction, and 
cell death; whereas mBDNF increases the capability for eliciting 
long-term potentiation, synaptic formation, and cell survival 
(see Lu et al., 2005). In neurons, pro-BDNF is usually converted 
to the mature form in the extracellular space by proteases includ-
ing tissue plasminogen activator (tPA). Cerebral levels of tPA 
decline with age and this decline is exacerbated in rodent models 
of Alzheimer disease (Cacquevel, et al., 2007). Therefore, greater 
secretion of BDNF may not enhance cognitive and neuronal 
function unless the cleavage molecules are present to convert it 
from its precursor form to its mature form. In fact, greater secre-
tion of pro-BDNF into the synaptic space without an adequate 
concentration of cleavage molecules (e.g., tPA) to convert it to its 
mature form might result in cognitive impairment and decline 
instead of cognitive enhancement (Lu et al., 2005; Pang et al., 
2004). The Val/Val form of the BDNF polymorphism increases 
the regulated secretion and trafﬁ  cking of the pro-BDNF mol-
ecule (Egan et al., 2003), and we ﬁ  nd that this polymorphism is 
associated with a more rapid decline in cognitive function than 
their genetic counterparts that have reduced secretion of pro-
BDNF. Our result is clearly in line with the hypothesis that the 
enhancing role of BDNF on cognition is dependent on a number 
of molecular factors including those that inﬂ  uence the presence 
or concentration of the cleavage molecules and that these sup-
porting molecules might also be affected by aging. In short, a 
complex array of molecules are involved in BDNF signaling, and 
increased cellular secretion due to a genetic polymorphism may 
not always be associated with better function.
Third, a number of environmental factors inﬂ  uence BDNF 
translation and concentration in rodents including environ-
mental enrichment (van Praag et al., 2000), physical exercise 
(Cotman et al., 2007), caloric restriction (Mattson et al., 2003), 
and estrogen administration (Scharfman and Maclusky, 2005). 
Interactions between the BDNF polymorphism and any of these 
environmental factors could be moderating the age-interaction 
observed in this study. In short, there are a multitude of reasons 
for why older adult Met carriers would demonstrate spared cog-
nitive function while Val homozygotes undergo a greater decline 
in cognitive function with advanced age.
It is also important to note that we did not ﬁ  nd that the 
BDNF polymorphism disproportionately affected one of the Frontiers in Human Neuroscience  | September  2008 | Volume  2 | Article  11
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task-switching conditions more than the other. That is, the switch 
cost (switch RT – repeat RT) was only marginally related to the 
BDNF polymorphism (p  =  0.08). This result suggests that the 
BDNF polymorphism, and its role in inﬂ  uencing the trajectory of 
cognitive decline in old age, may primarily affect decline in speed 
of processing rather than a domain speciﬁ  c decline in executive 
function. More research employing a wider variety of tasks is war-
ranted to examine this hypothesis.
It is also interesting to consider our results within a cognitive 
reserve framework in which individuals with more education 
often demonstrate spared cognitive function despite having dis-
ease-related pathology (Fratiglioni and Wang, 2007). We found 
that BDNF heterozygous individuals that performed more 
poorly 10 years earlier showed more stability and reserve over 
the 10-year span. In our sample, IQ scores, which are often used 
as a measure of cognitive reserve, were unrelated to the BDNF 
genotype, suggesting that both homozygotes and heterozygotes 
had equivalent levels of ‘reserve’ as assessed by this measure. It 
might be possible that the BDNF genotype acts as a modera-
tor between cognitive reserve measures such as IQ or education 
and cognitive function. This hypothesis would predict that Val/
Val individuals with higher levels of education or IQ would not 
show the same rate of decline in performance as Val/Val indi-
viduals with lower education or IQ scores. A study with a larger 
sample size would be more capable of investigating this poten-
tial moderating relationship.
Finally, there are a number of limitations of the current study. 
First, although we have gained statistical power compared to 
cross-sectional studies by conducting within-subjects compari-
sons, we have lost statistical power by only being able to recruit 
53 out of the 124 original participants. Therefore, our small 
sample size could have precluded our ability to ﬁ  nd a signiﬁ  cant 
interaction with the COMT polymorphism. However, despite 
this small sample size, we were able to detect a signiﬁ  cant effect 
of the BDNF polymorphism on task-switching performance and 
our effect sizes were similar to those reported by prior studies 
(de Frias et al., 2004; Harris et al., 2005, 2006). Second, although 
we report that the individuals who returned for the follow-up 
session did not differ in age or sex from those who decline to 
return, it is possible that the 53 people who agreed to participate 
in this study were healthier, higher functioning, and may not be 
a representative sample of the BDNF or COMT polymorphisms 
in this age range. This potential bias could have affected the pat-
tern of results that we describe here. A longer longitudinal study 
with a larger sample size would be able to reduce this possible 
confound.
In sum, we report that the BDNF polymorphism, and not the 
COMT polymorphism, inﬂ  uences the rate of cognitive decline 
over a 10-year span in older adults. Both conditions of the task-
switching paradigm were affected by the BDNF polymorphism 
while general cognitive function as assessed by the MMSE and 
IQ tests was not related to the BDNF polymorphism. The Met 
carriers of the BDNF gene demonstrated spared function over 
the 10-year span while the Val homozygotes experienced a sig-
niﬁ  cant decline in performance. This result is inconsistent with 
a growing literature on the impact of the BDNF polymorphism 
on depression, cognitive function, and neural activity in young 
adults, but is partially consistent with at least one study in older 
adults (Harris et al., 2006). More longitudinal studies with larger 
sample sizes that employ a wider range of cognitive tests and a 
more comprehensive array of factors that could explain some 
individual differences (e.g., physical ﬁ  tness measurements) and 
possibly covary or interact with the BDNF and COMT polymor-
phisms would greatly enhance the interpretation of the results 
described in this study.
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